1 CURRICULUM VITAE – DANIEL ABRAMOWICZ ... - Oxford Journals

guidelines: a European Renal Best Practice (ERBP) position statement.
Nephrol Dial Transplant. 2009 Mar;24(3):719-27.
119. DE GROOT K, HARPER L, JAYNE DR, FLORES SUAREZ LF, GREGORINI G,
GROSS WL, LUQMANI R, PUSEY CD, RASMUSSEN N, SINICO RA, TESAR V,
VANHILLE P, WESTMAN K, SAVAGE CO; EUVAS (EUROPEAN VASCULITIS
STUDY GROUP).
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil
cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Intern Med. 2009 May 19;150(10):670-80.
120. NOËL C, ABRAMOWICZ D, DURAND D, MOURAD G, LANG P, KESSLER M,
CHARPENTIER B, TOUCHARD G, BERTHOUX F, MERVILLE P, OUALI N,
SQUIFFLET JP, BAYLE F, WISSING KM, HAZZAN M.
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant
recipients.
J Am Soc Nephrol. 2009 Jun;20(6):1385-92.
121. PESCOVITZ MD, NEZAKATGOO N, LORBER MI, NASHAN B, TEDESCO-SILVA
H JR, KASISKE BL, DE LA CRUZ FJ, RUSS G, CAMPISTOL J, KEOWN PA;
INTERNATIONAL SIROLIMUS STUDY GROUP.
PROSPECTIVE OBSERVATIONAL STUDY OF SIROLIMUS AS PRIMARY
IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION.
Transplantation. 2009 Oct 27; 88(8):1010-8.
122. GHISDAL L, BARON C, LE MEUR Y, LIONET A, HALIMI JM, REROLLE JP,
GLOWACKI F, LEBRANCHU Y, DROUET M, NOËL C, EL HOUSNI H, COCHAUX
P, WISSING KM, ABRAMOWICZ D, ABRAMOWICZ M.
TCF7L2 polymorphism associates with new-onset diabetes after transplantation.
J Am Soc Nephrol. 2009 Nov;20(11):2459-67.
123. WLODARCZYK Z, SQUIFFLET JP, OSTROWSKI M, RIGOTTI P, STEFONI S,
CITTERIO F, VANRENTERGHEM Y, KRÄMER BK, ABRAMOWICZ D,
OPPENHEIMER F, PIETRUCK F, RUSS G,
KARPF C, UNDRE N.
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney
transplantation: a randomized, open-label trial.
Am J Transplant. 2009 Nov;9(11):2505-13.
25